Lumretuzumab (RG7116) is a humanized, glycoengineered immunoglobulin-G1 antibody that binds with high sensitivity and specificity to the extracellular domain of the human epidermal growth factor receptor 3 (HER3) [5], one of the members of HER family receptors playing a critical role in tumor growth, proliferation, and progression of numerous epithelial malignancies (reviewed in [6,7]). Here, ERBB3 is linked to neoplasm.